Clinical Research Details
Title:
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
Purpose:
The purpose of this study is to determine if treatment with vaginal cuff brachytherapy followed by three cycles of chemotherapy reduces the rate of recurrence or death (i.e., increases recurrence-free survival) when compared to pelvic radiation therapy.
Study Number:
201988071509
Number of Patients:
562
Elgibility:
Participants may be eligible if they have had a hysterectomy and bilateral salpingo-oophorectomy. They must have high-risk, early stage endometrial carcinoma and have adequate bone marrow, renal, hepatic and neurologic function.
Treatment:
You will be assigned by chance to one of the following treatments: Participants in Treatment #1 will receive the current standard treatment, which is pelvic radiation therapy over five – six weeks. They may receive additional radiation therapy at the physician’s discretion. Participants in Treatment #2 will receive a different form of radiation therapy, called brachytherapy, along with chemotherapy. Treatment #2 will last at least nine weeks.
Principal Investigator:
Enrollment Phone:
(708) 327-3222